gms | German Medical Science

60. Jahrestagung der Deutschen Gesellschaft für Neuropathologie und Neuroanatomie (DGNN)

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie

26. - 28.08.2015, Berlin

Prion-like propagation of synucleinopathy in mice expressing wild-type alpha-synuclein

Meeting Abstract

  • Maria Eugenia Bernis - German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
  • Julius Tachu Babila - German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
  • Sara Breid - German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
  • Ullrich Wüllner - German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; University of Bonn, Department of Neurology, Bonn, Germany
  • corresponding author presenting/speaker Gültekin Tamgüney - German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie. 60th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN). Berlin, 26.-28.08.2015. Düsseldorf: German Medical Science GMS Publishing House; 2015. Doc15dgnnND7

doi: 10.3205/15dgnn07, urn:nbn:de:0183-15dgnn073

Veröffentlicht: 25. August 2015

© 2015 Bernis et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Question: Parkinson’s disease and multiple system atrophy (MSA) are synucleinopathies that are defined by the accumulation of aggregated and hyperphosphorylated alpha-synuclein within cells of the central nervous system. Recent evidence suggests that prion-like propagation along connected neurons results in the spreading of pathological forms of alpha-synuclein in the nervous system. We investigated whether human wild-type alpha-synuclein supports prion-like propagation of pathological alpha-synuclein in vivo.

Methods: We intrastriatally injected groups of adult Tg(SNCA)1Nbm/J mice with brain extracts from two patients with MSA, from two aged control subjects without neurological disorder, or with saline. Tg(SNCA)1Nbm/J mice do not express mouse but low levels of human wild-type alpha-synuclein and do not naturally develop any pathology or neurodegenerative disease. Injected mice were sacrificed at 3, 6, and 9 months post injection and were analyzed immunohistochemically and biochemically for the presence of pathological alpha-synuclein.

Results: Mice injected with brain extracts from MSA or aged control subjects but not saline showed progressive accumulation of aggregated alpha-synuclein in neurons of the central nervous system. Aggregates of alpha-synuclein were hyperphosphorylated and co-stained for ubiquitin and p62 that target proteins for degradation. Pathological alpha-synuclein aggregates were first detectable in the ipsilateral brain hemisphere and over time in the contralateral hemisphere and in more rostral and caudal areas.

Conclusions: Our findings show that brain extracts from MSA patients but not saline induce pathological changes in the central nervous system of Tg(SNCA)1Nbm/J mice. Our data corroborate that pathological alpha-synuclein may spread prion-like along neuronal networks. Furthermore, we show that human wild-type alpha-synuclein supports propagation of pathological alpha-synuclein. Interestingly, brain extracts from aged control subjects without neurological disorder equally induced synucleinopathy in the brains of Tg(SNCA)1Nbm/J mice suggesting that aged human brains can contain pathological forms of alpha-synuclein.